CD4 and neoplasm: We found that CD4CAR NK-92 cells exhibit robust anti-tumor cytotoxicity ex vivo against both adult and pediatric CD4+ lymphoma/leukemia cell lines, CD4+ T-cells isolated from umbilical cord blood, as well as against untreatable primary CD4+ T-cell malignancies from adult and pediatric patients.